NYSE
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies.
Roles derived from SEC Form 4 filings.
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $6.5B | $6.3B | $6.2B | $6.3B | $6.4B | $6.2B |
| Gross profit | — | — | $3.9B | $3.7B | $3.7B | $3.3B |
| Operating income | — | — | — | — | — | — |
| Net income | $2.2B | $1.4B | $917.0M | $1.0B | $864.0M | $187.0M |
| Diluted EPS | $8.52 | $5.31 | $3.59 | $3.99 | $3.33 | $0.72 |
| Operating cash flow | — | — | $858.0M | $799.0M | $939.0M | $700.0M |
| Free cash flow | — | — | $662.0M | $548.0M | $764.0M | $538.0M |
| Gross margin | — | — | 62.8% | 59.8% | 58.0% | 53.3% |
| Operating margin | — | — | — | — | — | — |
| Net margin | 33.1% | 21.4% | 14.9% | 16.3% | 13.5% | 3.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6B | $1.6B | $1.6B | $1.5B | $1.6B | $1.6B | $1.5B | $1.5B |
| Gross profit | $939.0M | $923.0M | $896.0M | $841.0M | $874.0M | $857.0M | $741.0M | $783.0M |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | $195.0M | $359.0M | $109.0M | $87.0M | $145.0M | $160.0M | -$205.0M | $146.0M |
| Diluted EPS | $0.75 | $1.38 | $0.42 | $0.33 | $0.56 | $0.61 | -$0.78 | $0.55 |
| Operating cash flow | $332.0M | $141.0M | $390.0M | $75.0M | $220.0M | $264.0M | $141.0M | $225.0M |
| Free cash flow | $300.0M | $99.0M | $335.0M | $43.0M | $181.0M | $218.0M | $96.0M | $188.0M |
| Gross margin | 58.4% | 58.3% | 56.3% | 55.6% | 54.8% | 53.5% | 49.2% | 53.6% |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | 12.1% | 22.7% | 6.8% | 5.8% | 9.1% | 10.0% | -13.6% | 10.0% |
Consensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-06 | Holzbaur Lynette· SVP and Corporate Controller | Sale | 26,448 | $13.35 | $353,080.40 | filing |
| 2026-05-06 | Holzbaur Lynette· SVP and Corporate Controller | Buy | 26,448 | $13.35 | $353,080.40 | filing |
| 2026-05-06 | Holzbaur Lynette· SVP and Corporate Controller | J | 46 | $0.00 | $0.00 | filing |
| 2026-03-31 | WALSH MATTHEW M· Chief Financial Officer | Tax withholding | 7,380 | $5.70 | $42,066.00 | filing |
| 2026-03-31 | Arjona Ferreira Juan Camilo· Head of R&D & CMO | Tax withholding | 4,820 | $5.70 | $27,474.00 | filing |
| 2026-03-31 | Morrissey Joseph T. Jr.· Interim CEO | Tax withholding | 4,784 | $5.70 | $27,268.80 | filing |
| 2026-03-31 | Stahler Rachel A· Chief Information Officer | Tax withholding | 4,217 | $5.70 | $24,036.90 | filing |
| 2026-03-31 | WALSH MATTHEW M· Chief Financial Officer | Tax withholding | 4,127 | $5.70 | $23,523.90 | filing |
| 2026-03-31 | Falcione Aaron· Chief Human Resources Officer | Tax withholding | 3,834 | $5.70 | $21,853.80 | filing |
| 2026-03-31 | Karp Daniel· Executive VP, Corp. Dev. | Tax withholding | 3,554 | $5.70 | $20,257.80 | filing |
| 2026-03-31 | Weaver Kirke· Gen. Counsel & Corp. Secy. | Tax withholding | 3,508 | $5.70 | $19,995.60 | filing |
| 2026-03-31 | Drinane Juliana Papa· Interim Head of Mfg & Supply | Tax withholding | 3,451 | $5.70 | $19,670.70 | filing |
| 2026-03-31 | Nisita Vittorio· Head of Global Business Svcs | Tax withholding | 2,875 | $5.70 | $16,387.50 | filing |
| 2026-03-31 | Falcione Aaron· Chief Human Resources Officer | Tax withholding | 2,306 | $5.70 | $13,144.20 | filing |
| 2026-03-31 | Stahler Rachel A· Chief Information Officer | Tax withholding | 2,246 | $5.70 | $12,802.20 | filing |
| 2026-03-31 | Morrissey Joseph T. Jr.· Interim CEO | Tax withholding | 2,221 | $5.70 | $12,659.70 | filing |
| 2026-03-31 | Drinane Juliana Papa· Interim Head of Mfg & Supply | Tax withholding | 2,185 | $5.70 | $12,454.50 | filing |
| 2026-03-31 | Karp Daniel· Executive VP, Corp. Dev. | Tax withholding | 2,105 | $5.70 | $11,998.50 | filing |
| 2026-03-31 | Holzbaur Lynette· SVP and Corporate Controller | Tax withholding | 1,914 | $5.70 | $10,909.80 | filing |
| 2026-03-31 | Weaver Kirke· Gen. Counsel & Corp. Secy. | Tax withholding | 1,767 | $5.70 | $10,071.90 | filing |
| 2026-03-31 | Nisita Vittorio· Head of Global Business Svcs | Tax withholding | 1,578 | $5.70 | $8,994.60 | filing |
| 2026-03-31 | Holzbaur Lynette· SVP and Corporate Controller | Tax withholding | 1,212 | $5.70 | $6,908.40 | filing |
| 2026-03-31 | WALSH MATTHEW M· Chief Financial Officer | Option exercise | 21,546 | $0.00 | $0.00 | filing |
| 2026-03-31 | Falcione Aaron· Chief Human Resources Officer | Option exercise | 11,193 | $0.00 | $0.00 | filing |
| 2026-03-31 | WALSH MATTHEW M· Chief Financial Officer | Option exercise | 12,047 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.